Management pointed to strong execution in acute therapies and a transitional period in chronic therapies. Rademacher said acute revenue grew in the “high single digits, well above market growth,” attributing momentum to strengthening patient transitions, expanding referral relationships, and focusing on “clinical value realization.”Rademacher highlighted continued patient experience metrics, saying the company is still posting “patient satisfaction scores in the low 90s and Net Promoter Score in the mid-70s ...